All In Biotech

Drug Trial Radar · NCT06615050

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 572 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

572

Planned (sponsor's estimate)

Start

Apr 2, 2025

Primary completion

Jan 17, 2031

Study completion Jan 17, 2031

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
Blood and Marrow Transplant Clinical Trials Network; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Conditions

  • Graft-versus-host Disease (GVHD)

Interventions

  • Tacrolimus (Tac)Drug

    Tablet or intravenously (IV)

  • Methotrexate (MTX)Drug

    Intravenously (IV)

  • Ruxolitinib (Rux)Drug

    Tablet

  • CyclophosphamideDrug

    Intravenously (IV)

  • Mycophenolate mofetil (MMF)Drug

    Tablet or intravenously (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GVHD-free survival (GFS)Time frame: Up to 24 months post-transplant (Day 0)

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford Cancer Center

    Palo Alto, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Blood and Marrow Transplant Group of Georgia

    Atlanta, Georgia · Recruiting

  • Indiana University Cancer Center

    Indianapolis, Indiana · Recruiting

  • University of Kansas Hospital Authority

    Kansas City, Kansas · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Mount Sinai Hospital

    New York, New York · Recruiting

  • Memorial Sloan Kettering

    New York, New York · Recruiting

  • University of North Carolina At Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Sarah Cannon

    Nashville, Tennessee · Recruiting

  • Vanderbilt Medical Center

    Nashville, Tennessee · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • Virginia Commonwealth University, North Hospital

    Richmond, Virginia · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.